Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART

M. P. Carrieri; D. Vlahov; P. Dellamonica; H. Gallais; G. Lepeu; B. Spire; Y. Obadia

doi:10.1016/S0376-8716(00)80007-1

Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART

M. P. Carrieri, D. Vlahov, P. Dellamonica, H. Gallais, G. Lepeu, B. Spire, Y. Obadia

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Some HIV-infected injecting drug users (IDUs) on drug abuse maintenance treatment have access to highly active antiretroviral therapy (HAART); this raises questions about the effects of individual treatments on the efficacy of HAART. The French Cohort Study of HIV-infected IDUs - MANIF-2000 - allowed one to assess whether buprenorphine differentially impacts efficacy of HAART. Of the 103 HAART-treated patients, (excluding active IDUs and patients on methadone), 20 were on buprenorphine substitution treatment and 83 were ex-IDUs. A linear regression model used the differences in viral load titre before and after treatment initiation, as a dependent variable, and showed that buprenorphine treatment was not significantly associated with viral load trend. This was also the case when adjusting for other potential confounders, and suggests that there is no major short-term influence of buprenorphine on HIV viral load in HAART-treated patients. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original language	English (US)
Pages (from-to)	51-54
Number of pages	4
Journal	Drug and alcohol dependence
Volume	60
Issue number	1
DOIs	https://doi.org/10.1016/S0376-8716(00)80007-1
State	Published - Jul 1 2000

Keywords

Buprenorphine
Drug maintenance treatment
HIV
Injection drug users
Viral load

ASJC Scopus subject areas

Toxicology
Pharmacology
Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.1016/S0376-8716(00)80007-1

Cite this

@article{1956afa3eff54d31b948728c55c8db9d,

title = "Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART",

abstract = "Some HIV-infected injecting drug users (IDUs) on drug abuse maintenance treatment have access to highly active antiretroviral therapy (HAART); this raises questions about the effects of individual treatments on the efficacy of HAART. The French Cohort Study of HIV-infected IDUs - MANIF-2000 - allowed one to assess whether buprenorphine differentially impacts efficacy of HAART. Of the 103 HAART-treated patients, (excluding active IDUs and patients on methadone), 20 were on buprenorphine substitution treatment and 83 were ex-IDUs. A linear regression model used the differences in viral load titre before and after treatment initiation, as a dependent variable, and showed that buprenorphine treatment was not significantly associated with viral load trend. This was also the case when adjusting for other potential confounders, and suggests that there is no major short-term influence of buprenorphine on HIV viral load in HAART-treated patients. Copyright (C) 2000 Elsevier Science Ireland Ltd.",

keywords = "Buprenorphine, Drug maintenance treatment, HIV, Injection drug users, Viral load",

author = "Carrieri, {M. P.} and D. Vlahov and P. Dellamonica and H. Gallais and G. Lepeu and B. Spire and Y. Obadia",

note = "Funding Information: This study was supported by the ANRS (France), ECS-SIDACTION (France), and Departmental Council (Bouches-du-Rhone, France). Dr Vlahov was supported by The National Institute on Drug Abuse (DA 04334).",

year = "2000",

month = jul,

day = "1",

doi = "10.1016/S0376-8716(00)80007-1",

language = "English (US)",

volume = "60",

pages = "51--54",

journal = "Drug and Alcohol Dependence",

issn = "0376-8716",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Use of buprenorphine in HIV-infected injection drug users

T2 - Negligible impact on virologic response to HAART

AU - Carrieri, M. P.

AU - Vlahov, D.

AU - Dellamonica, P.

AU - Gallais, H.

AU - Lepeu, G.

AU - Spire, B.

AU - Obadia, Y.

N1 - Funding Information: This study was supported by the ANRS (France), ECS-SIDACTION (France), and Departmental Council (Bouches-du-Rhone, France). Dr Vlahov was supported by The National Institute on Drug Abuse (DA 04334).

PY - 2000/7/1

Y1 - 2000/7/1

N2 - Some HIV-infected injecting drug users (IDUs) on drug abuse maintenance treatment have access to highly active antiretroviral therapy (HAART); this raises questions about the effects of individual treatments on the efficacy of HAART. The French Cohort Study of HIV-infected IDUs - MANIF-2000 - allowed one to assess whether buprenorphine differentially impacts efficacy of HAART. Of the 103 HAART-treated patients, (excluding active IDUs and patients on methadone), 20 were on buprenorphine substitution treatment and 83 were ex-IDUs. A linear regression model used the differences in viral load titre before and after treatment initiation, as a dependent variable, and showed that buprenorphine treatment was not significantly associated with viral load trend. This was also the case when adjusting for other potential confounders, and suggests that there is no major short-term influence of buprenorphine on HIV viral load in HAART-treated patients. Copyright (C) 2000 Elsevier Science Ireland Ltd.

AB - Some HIV-infected injecting drug users (IDUs) on drug abuse maintenance treatment have access to highly active antiretroviral therapy (HAART); this raises questions about the effects of individual treatments on the efficacy of HAART. The French Cohort Study of HIV-infected IDUs - MANIF-2000 - allowed one to assess whether buprenorphine differentially impacts efficacy of HAART. Of the 103 HAART-treated patients, (excluding active IDUs and patients on methadone), 20 were on buprenorphine substitution treatment and 83 were ex-IDUs. A linear regression model used the differences in viral load titre before and after treatment initiation, as a dependent variable, and showed that buprenorphine treatment was not significantly associated with viral load trend. This was also the case when adjusting for other potential confounders, and suggests that there is no major short-term influence of buprenorphine on HIV viral load in HAART-treated patients. Copyright (C) 2000 Elsevier Science Ireland Ltd.

KW - Buprenorphine

KW - Drug maintenance treatment

KW - HIV

KW - Injection drug users

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=0343183993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0343183993&partnerID=8YFLogxK

U2 - 10.1016/S0376-8716(00)80007-1

DO - 10.1016/S0376-8716(00)80007-1

M3 - Article

C2 - 10821989

AN - SCOPUS:0343183993

SN - 0376-8716

VL - 60

SP - 51

EP - 54

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

IS - 1

ER -

Use of buprenorphine in HIV-infected injection drug users: Negligible impact on virologic response to HAART

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this